Rundu Co., Ltd.: 2024 performance forecast

SZSIJan 23 00:00 · Announcements

Express News | Zhuhai Rundu Pharmaceutical: It is expected that the net income in 2024 will decrease by 40.21% to 58.15% year-on-year.

BreakingsJan 22 16:17

Zhuhai Rundu Pharmaceutical (002923.SZ): The subsidiary Zhuhai Rundu Pharmaceutical (Jingmen) Co., Ltd. produces nicotine, which includes synthetic nicotine and extracted nicotine.

On December 18, Glonghui reported that Zhuhai Rundu Pharmaceutical (002923.SZ) stated on the investor interaction platform that its subsidiary, Rundu Pharmaceutical (Jingmen) Co., Ltd., produces nicotine both from synthetic sources and extraction.

Gelonghui FinanceDec 18, 2024 14:41

Rundu Pharmaceutical Gets Regulatory Nod to Add Specification for Irbesartan Tablets

MT NewswiresNov 14, 2024 13:37

Zhuhai Rundu Pharmaceutical (002923.SZ): The approval notice for the supplementary application of Irbesartan tablets was received.

On November 13, Gelonghui reported that Zhuhai Rundu Pharmaceutical (002923.SZ) announced that the company recently received the "Notification of Approval for Supplementary Application for Pharmaceutical" issued by the National Medical Products Administration. The pharmaceutical name is Irbesartan tablets, and the National Medical Products Administration approved an additional specification of 75mg, issued a pharmaceutical approval number, and the new specification product will be packaged in solid oral high-density polyethylene bottles. Irbesartan tablets are indicated for the treatment of primary hypertension and the treatment of type 2 diabetic nephropathy with hypertension.

Gelonghui FinanceNov 13, 2024 16:57

Express News | Zhuhai Rundu Pharmaceutical: The addition of a new 75mg specification for Irbesartan Tablets has been approved.

BreakingsNov 13, 2024 16:53